

## ELEMENTS OF BUPRENORPHINE TREATMENT REFERENCES

1. ASAM Board of Directors. [ASAM Public Policy Statement: Definition of Addiction](#). 2011.
2. SAMHSA. [Treatments for Substance Use Disorders](#). 2015.
3. FSMB. [Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office](#). *FSMB Website*. 2013.
4. American Psychiatric Association. [Substance-Related and Addictive Disorders](#). *APA*. 2013.
5. USDHHS. [Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements](#). 2016.
6. Reuter N. *Personal Communication via E-Mail Re: Buprenorphine Waivered Physicians*. 2011.
7. SAMHSA. [Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update](#). Winter 2016.
8. American Society of Addiction Medicine (ASAM). [Drug Testing As A Component Of Addiction Treatment and Monitoring Programs and in Other Clinical Settings](#). *ASAM.org*. 2010.
9. Reisfield Gary M, Maschke Karen J. [Urine Drug Testing in Long-Term Opioid Therapy: Ethical Considerations](#). *Clin J Pain*. 2014;30(8):679-684. doi:10.1097/01.ajp.0000435448.34761.c9.
10. Gourlay D. [Urine Drug Testing in Chronic Pain: A Patient Centered Approach \(AMA\) \[webinar\]](#). 2013.
11. Manchikanti L, Manchukonda R, Damron KS. [Does adherence monitoring reduce controlled substance abuse in chronic pain patients?](#). *Pain Physician*. 2006;9(1):57-60.
12. Chou Roger, Fanciullo Gilbert J, Fine Perry G, et al. [Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain](#). *J Pain Off J Am Pain Soc*. 2009;10(2):113-130. doi:10.1016/j.jpain.2008.10.008.